Böhle A, Schüller J, Knipper A
Klinik für Urologie, Medizinischen Universität zu Lübeck.
Urologe A. 1989 Jan;28(1):36-9.
Nine patients with radiologically proven vesicorenal reflux (3 bilateral, 4 unilateral, 2 with unilateral double-J stents) received intravesical bacillus Calmette-Guérin (BCG) as prophylactic treatment for recurrent superficial bladder carcinoma. One patient with a double-J stent suffered an attack of high fever, probably following obstruction of the stent. All other patients tolerated one cycle or two cycles (5 of 9 patients) of 6 weekly instillations without significant complications. There was no increased toxicity compared with a control group of 39 patients without reflux who were receiving BCG. Topical intravesical immunotherapy with BCG in patients with vesicorenal reflux can be given without a rise in the complication rate; indeed, in view of the multifocal appearance of urothelial carcinoma in this subgroup, this type of therapy even appears to be desirable.
9例经放射学证实存在膀胱输尿管反流的患者（3例双侧反流，4例单侧反流，2例单侧置入双J管）接受了膀胱内卡介苗（BCG）灌注，作为复发性浅表性膀胱癌的预防性治疗。1例置入双J管的患者出现高热发作，可能是由于支架堵塞所致。所有其他患者耐受了6周1次、共1个周期或2个周期（9例患者中的5例）的灌注，无明显并发症。与39例无反流且接受BCG治疗的对照组相比，毒性并未增加。膀胱输尿管反流患者采用BCG进行膀胱内局部免疫治疗，并发症发生率不会升高；实际上，鉴于该亚组尿路上皮癌多灶性的表现，这种治疗方式甚至似乎是可取的。
